Full-Time

Senior Marketing Manager

Sales Enablement

Calyxo

Calyxo

201-500 employees

Develops and markets kidney stone devices

Compensation Overview

$180k - $195k/yr

+ Variable incentive plan

Pleasanton, CA, USA

Hybrid

Category
Sales & Account Management
Required Skills
Product Management
Marketing
Requirements
  • Education: Equivalent work experience or Bachelor’s degree in marketing, business administration, or a related field; MBA preferred
  • Minimum of 7+ years of experience in downstream marketing, sales enablement, or commercial roles within the medical device industry
  • Excellent communication and interpersonal skills with the ability to collaborate effectively with Sales, Training, and cross-functional teams
  • Ability to translate strategic direction and market insights into clear, compelling, and practical sales enablement materials
  • Results-oriented with a focus on driving field adoption, utilization of tools, and commercial impact
  • Knowledge of regulatory requirements and compliance standards for medical devices, with the ability to ensure all sales materials meet appropriate guidelines
  • Ability to translate clinical messaging into clear, field-ready value propositions and customer-facing materials
  • Ideally a hybrid background in sales + marketing
  • High bias for action and practical execution
  • Work Location: Pleasanton
  • Travel: 25% travel
Responsibilities
  • Translate messaging frameworks into sales tools, presentations, and training materials in close partnership with Sales Leadership and Sales Training
  • Own sales enablement strategy and execution across key initiatives
  • Develop tools that support clinical conversations and objection handling in real-world customer interactions
  • Ensure materials are practical, usable, and aligned with field workflows and feedback
  • Support national meetings, trainings, and field communications
  • Gather field feedback and continuously refine tools for effectiveness
  • Partner closely with Sales Leadership and Field Training to develop and deliver field-ready tools, programs, and communications that support physician engagement and procedural adoption
  • Act as a key stakeholder with Strategic Marketing to translate messaging frameworks and positioning into practical, customer-facing materials
  • Collaborate with MarCom to ensure all deliverables are high-quality, on-brand, and effectively executed across formats and channels
  • Work cross-functionally with internal teams as needed (e.g., Medical and Clinical Affairs, Market Access, Product Management) to ensure materials are accurate, relevant, and aligned with broader commercial strategy
Desired Qualifications
  • None

Calyxo, Inc. develops medical devices for kidney stone treatment. Its products are designed for use by urologists in hospitals and clinics to treat kidney stones more effectively, prioritizing patient safety and efficient procedures. The company works closely with leading U.S. urologists to translate clinical needs into devices, focusing on making treatments safer and easier for clinicians. Unlike some competitors, Calyxo emphasizes clinician collaboration and proven clinical relevance in its device development, backed by leadership with startup and product-launch experience. The goal is to improve patient care by delivering advanced devices that help urologists achieve better clinical outcomes and expand the devices’ reach through commercialization to healthcare providers.

Company Size

201-500

Company Stage

Series F

Total Funding

$137.2M

Headquarters

Pleasanton, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Calyxo raised $40 million in Series F from specialist healthcare investors.
  • CVAC crossed 40,000 kidney stone procedures, strengthening physician referenceability.
  • Funding supports commercial expansion and health-economic evidence generation.

What critics are saying

  • Boston Scientific already owns installed ureteroscopy franchises in most hospitals.
  • A 2024 MAUDE report documented sepsis and death after CVAC use.
  • Calyxo still depends on early evidence; larger studies can narrow differentiation.

What makes Calyxo unique

  • CVAC continuously aspirates stone fragments during and after laser lithotripsy.
  • FDA cleared CVAC in March 2024, lowering regulatory friction.
  • ASPIRE showed superior stone clearance and lower residual stone volume versus URS.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Calyxo who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

8%
StreetInsider
Apr 14th, 2026
Calyxo raises $40M Series F as CVAC kidney stone system treats 40,000 patients

Calyxo, a medical device company focused on kidney stone treatment, has closed a $40 million Series F financing round led by Ally Bridge Group and Janus Henderson Investors. Questa Capital, Avidity Partners and CRG also participated. The funding follows a milestone of 40,000 patients treated with Calyxo's CVAC System, an aspiration-based stone removal device. The system uses irrigation and vacuum aspiration to continuously clear stone fragments during procedures, enabling more complete stone clearance. Proceeds will support commercial expansion, clinical evidence generation through ongoing studies evaluating long-term outcomes, and continued innovation in kidney stone care. The CVAC System received FDA clearance in 2024 and is positioned as an all-in-one solution for minimally invasive kidney stone removal.

Business Wire
May 14th, 2024
Study Presented At Aua Shows Superior Kidney Stone Clearance Rates For Sure Procedure Using Calyxo’S Cvac System Vs Standard Urs

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups

Business Wire
Mar 26th, 2024
Calyxo Announces Fda Clearance For New, Redesigned Cvac System

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback. Clinical studies have shown that residual stone fragments are associated with a 20%-44% incidence of post-procedure problems, including pain, infection, emergency department visits, hospitalization and need for retreatment. Steerable ureteroscopic renal evacuation (SURE) using the original CVAC Aspiration System has been used to successfully treat more than 1,500 patients in the U.S., demonstrating that vacuum aspiration of stone fragments improves clinical outcomes, with 97% volumetric stone clearance and a high likelihood of avoiding the need for a secondary or more invasive procedure (according to clinical study data collected in patients treated with the device)

FinSMEs
Dec 12th, 2023
Calyxo Raises $50M in Series D Funding

Calyxo, a Pleasanton, CA-based medical device company developing next-generation treatment solutions for patients with kidney stones, raised $50M in Series D funding.

Questa Capital
Jul 6th, 2022
Questa Capital invests into Calyxoinc in $32.7M

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.